Expected Moves

Benchmark Holdings will report Q3 2026 results, providing investors a first comprehensive look at operating margins and cash burn for the Advanced Nutrition and Health segments following the divestiture of its Genetics division.

Management is expected to address the company's distressed 12.4x Net Debt/EBITDA leverage ratio. A potential debt restructuring, dilutive equity raise, or further asset sales will be critical for avoiding liquidity cliffs in 2027.

Full-year 2026 results will detail the complete financial impact of the streamlined operating model, providing FY 2027 guidance for the remaining Health and Advanced Nutrition portfolios.

Q1 2027 earnings will focus on seasonal Advanced Nutrition sales, particularly in the shrimp and marine finfish markets, alongside free cash flow generation to service ongoing debt obligations.

Benchmark is anticipated to provide a commercial update on its new water purification and sea lice treatment solutions, including Ectosan Vet and Purisan, across key international markets like Norway and Chile.

Q2 2027 earnings will serve as a crucial barometer for the Health segment's margin expansion and the broader commercial adoption of Benchmark's aquaculture sustainability solutions.